ClinVar Miner

Submissions for variant NM_000426.3(LAMA2):c.2049_2050delAG (rs202247790)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000078754 SCV000226026 pathogenic not provided 2013-11-08 criteria provided, single submitter clinical testing
Center for Genetic Medicine Research,Children's National Medical Center RCV000230453 SCV000265783 uncertain significance not specified 2015-12-01 criteria provided, single submitter research
GeneDx RCV000078754 SCV000583109 pathogenic not provided 2018-12-13 criteria provided, single submitter clinical testing The c.2049_2050delAG variant in the LAMA2 gene has been previously reported in individuals with merosin-deficient congenital muscular dystrophy who harbor an additional LAMA2 variant (Guicheney et al., 1998; Yang et al., 2015). The c.2049_2050delAG variant is observed in 5/24028 (0.0208%) alleles from individuals of African background and 34/277008 total alleles in large population cohorts, and no individuals were reported to be homozygous (Lek et al., 2016). The c.2049_2050delAG variant causes a frameshift starting with codon Arginine 683, changes this amino acid to a Serine residue and creates a premature Stop codon at position 21 of the new reading frame, denoted p.Arg683SerfsX21. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. We interpret c.2049_2050delAG as a pathogenic variant.
Invitae RCV000557045 SCV000658642 pathogenic Laminin alpha 2-related dystrophy 2020-01-02 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg683Serfs*21) in the LAMA2 gene. It is expected to result in an absent or disrupted protein product. This variant is present in population databases (rs751627052, ExAC 0.01%). This variant has been reported in the literature in multiple individuals affected with congenital muscular dystrophy (PMID: 9541105, 25544356, 18700894, 24611677). This variant is also known in the literature as 2098delAG and p.Lys682Lysfs*22. ClinVar contains entries for this variant (Variation ID: 38340, 216956). Loss-of-function variants in LAMA2 are known to be pathogenic (PMID: 18700894). For these reasons, this variant has been classified as Pathogenic.
Mendelics RCV000031899 SCV001137216 pathogenic Merosin deficient congenital muscular dystrophy 2019-05-28 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000078754 SCV001247102 pathogenic not provided 2018-07-01 criteria provided, single submitter clinical testing
Centre for Mendelian Genomics,University Medical Centre Ljubljana RCV001197166 SCV001367802 likely pathogenic Neuromuscular disorder 2016-01-01 criteria provided, single submitter clinical testing This variant was classified as: Uncertain significance. The following ACMG criteria were applied in classifying this variant: PM1,PP3. This variant was detected in heterozygous state.
GeneReviews RCV000031899 SCV000054523 pathologic Merosin deficient congenital muscular dystrophy 2012-06-07 no assertion criteria provided curation Converted during submission to Pathogenic.
Counsyl RCV000031899 SCV001132421 pathogenic Merosin deficient congenital muscular dystrophy 2017-01-03 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.